Pharmacoki0netic profiles of rizatriptan benzoate nasal solution in rats

Min ZHANG,Keming SUN,Xianyong LIU,Jun CHEN,Shijun LIU

DOI: https://doi.org/10.19577/j.cnki.issn10074406.2017.03.006

2017-01-01

Abstract:AIM To study the pharmacokinetic profiles of rizatriptan benzoate(RIZA) nasal solution in rats,and to compare the corresponding pharmacokinetic parameters with intravenous and oral formulations.METHODS Totally 15 SD rats were randomly divided into 3 groups,each group was intranasal,intravenous and oral administrated with RIZA at the dosage of 2.5 mg · kg-1.The plasma concentration of RIZA was determined by HPLC method with fluorescence detection.Main pharmacokinetic parameters were calculated and statistically analyzed.RESULTS The main pharmacokinetic parameters of RIZA nasal solution were as follows:ρmax were (608 ±67) μg · L-1,tmaxwere (0.65 ±0.14) h,AUC0-t were (1 380 ±87) μg · L-1 · h;the main pharmacokinetic parameters of RIZA intravenous injectionwere as follows:pmax were (1 135 ± 110) μg · L-1,AUC0-t were (2 167 ±261) μg · L-1 · h;the main pharmacokinetic parameters of RIZA oral solution were as follows:ρmax were (144 ±28) μg · L-1,tmax were (0.85 ±0.14) h,AUC0-t were (442 ±110) μg · L-1 · h.The absolute bioavailability of nasal solution was 63.68％,which was 2.12 times higher than the oral formulation.CONCLUSION The nasal formulation has a high bioavailability relative to the oral solution,indicating that the formulation is expected to improve the therapeutic effect of migraine.The HPLC method proved to be sensitive,specify and repeatable enough to be used in pharmacokinetic studies.